Mycophenolate Mofetil in Membranous Nephropathy
Phase 2
Completed
- Conditions
- Glomerulonephritis, Membranous
- Registration Number
- NCT00135967
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects.
In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Membranous nephropathy
- Serum creatinine (Screat)> 1,5 mg/dl or ECC < 70 ml/min or increase Screat > 50%
- Proteinuria > 2 g/day
Exclusion Criteria
- Systemic diseases
- Pregnancy wish
- Active infection
- Liver dysfunction
- Abnormal hematology lab
- Unstable angina
- Nonsteroidal anti-inflammatory agents (NSAIDs)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method renal function (serum creatinine) proteinuria
- Secondary Outcome Measures
Name Time Method side effects relapse rate
Trial Locations
- Locations (1)
Department of Nephrology Radboud University Nijmegen Medical Centre
🇳🇱Nijmegen, Netherlands